KDR and neoplasm: For example, apatinib, an oral receptor tyrosine kinase inhibitor that selectively targets VEGFR2, can inhibit the downstream signaling of VEGFR2 and has good anti-tumor effects on a variety of tumors, including CRC [8,31,32].